AtlasGEN Novel Drug Designer
Generative AI platform for novel drug discovery with pre-validated hits and vast chemical search space
Platform · Cloud SaaSCompany source
Company profile
About VeriSIM Life
VeriSIM Life is a drug discovery and development company that leverages artificial intelligence to accelerate the translation of drug candidates to clinical trials. The company's flagship platform, BIOiSIM, is a first-in-class decision engine that combines chemical and biological modeling with AI and machine learning to predict how drugs will affect patients. The platform's proprietary Translational Index technology evaluates drug candidates across multiple dimensions including safety, toxicity, efficacy, pharmacokinetics, and pharmacodynamics. BIOiSIM features an inferential search space of 1 billion drug-like compounds, 10 billion network effects in deep learning algorithms, and 800 billion potential simulation scenarios. The platform achieves 83% average accuracy in predictions from structure-only inputs and has been validated through 1.5 million real simulations. VeriSIM Life's technology addresses critical pain points in drug development including drug repurposing, formulation optimization, drug-drug interactions, and patient stratification. The company also operates PulmoSIM Therapeutics, a wholly-owned brand that identifies licensable candidates for preclinical translation and out-licensing. VeriSIM Life serves pharmaceutical companies, biotechnology firms, and academic research institutions through AI-driven services and risk-sharing collaborations. The company's mission is to eliminate inaccuracy and waste in translating drug candidates to clinical trials, ultimately addressing the unmet needs of patients with rare and complex diseases.
Company description VeriSIM Life official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at VeriSIM Life?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- 9500 unmet diseases mentioned
- erectile dysfunction
- stimulant use disorder
Who it serves
- Academic institutions
- Biotechnology firms
- Pharmaceutical companies
- Research institutions
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
NIH Phase II STTR grant awarded for stimulant use disorder therapeutics discovery; FDA/NCTR research collaboration formalized; Dr. Jo Varshney named to Inc.'s Female Founders 500
Partnerships
Recorded partners
- FDA/NCTR (National Center for Toxicological Research)
- multiple proprietary data partnerships
- NIH/NIDA (National Institute on Drug Abuse)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
BIOiSIM
AI-driven decision engine for drug discovery and R&D de-risking with Translational Index technology
Platform · Cloud SaaSCompany source
Drug Formulation Solution
AI-driven platform addressing formulation challenges including solubility, stability, and dose optimization
Platform · Cloud SaaSCompany source
Drug Repurposing Solution
AI-powered platform for identifying new uses for existing drugs with reduced development risk
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
83% average accuracy
predictions from structure-only inputs
82% more accurate
than mechanistic non-informed tools
72% more efficient
protein-ligand binding affinity prediction vs molecular docking
80%+ accuracy
therapeutic window and optimal dosing predictions validated by CRO
Biotech Client (Erectile Dysfunction Therapy)
Repurposing and developing a topical formulation for erectile dysfunction containing three known drugs, determining feasibility of different route of administration
80%+ accuracy in identifying different route of administration, validated therapeutic window and predicted optimal dosing for three compound-mixes. Client filed IP and applied for IND approval.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jo Varshney
Founder & CEO
06 · Company updates
Updates from VeriSIM Life
Recent articles published on VeriSIM Life's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.